Global Tuberculosis Diagnostics Market Size

Tuberculosis Diagnostics Market Analysis

The Global Tuberculosis Diagnostics Market size is estimated at USD 2.44 billion in 2024, and is expected to reach USD 3.24 billion by 2029, growing at a CAGR of 5.87% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the data', it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has negatively impacted the market growth during the pandemic.

Certain factors that are propelling the market growth are the increasing burden of tuberculosis and multidrug-resistant tuberculosis (MDR-TB), increasing research and development investments and intensive product pipelines and increasing government initiatives, and rising awareness in the emerging markets.

The rising incidences of tuberculosis and multi-drug resistant tuberculosis (MDR-TB) is the key factor driving the market growth. For instance, according to the Global Tuberculosis Report 2021 published by the World Health Organization, in October 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), and Europe (2.3%). Additionally, according to the data published by the World Health Organization (WHO), in October 2021, about 1.5 million people worldwide died because of tuberculosis (TB), in 2020, and approximately 10 million people fell ill with tuberculosis globally. Thus, the rising burden of tuberculosis among the population increases the need for better diagnostic tests and treatment, which in turn is anticipated to propel the market growth over the forecast period.

Additionally, according to an article published by the Journal of Family Medicine and Primary Care, in January 2022, titled 'Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal', it has been observed that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is highest in India and ranks first in the global ranking of detecting new cases each year. In addition, as per the same source, an estimated overall incidence of tuberculosis in India was 193 per lakh people, in 2020. Similarly, as per the latest report of the Government of India published in March 2021, there were an estimated 1,24,000 instances of MDR/RR-TB in India (9.1 lakh people), in 2021. Thus, the rising burden of MDR-TB cases among the population is expected to increase the demand for early diagnosis of the disease for further treatment, which in turn is anticipated to augment the market growth over the forecast period.

Furthermore, the growing company's focus on research and development activities and intensive product pipelines are also contributing to the growth of the market. For instance, in October 2021, Qiagen launched the QIAreach QuantiFERON-TB test, built on the proven QuantiFERON-TB Gold Plus technology for tuberculosis (TB) infection. Also, in July 2020, The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, launched a new drug-resistant tuberculosis profiling test, Xpert MTB/XDR, that can be used to empower clinicians to quickly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB). The test can give a result in 90 minutes.

However, the high costs associated with tuberculosis diagnostics and low coverage or absence of insurance in the emerging markets are some of the factors that are hindering the market growth over the forecast period.